title: Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy.
abstract: A key barrier against developing preventive and therapeutic human immunodeficiency virus (HIV) vaccines is the inability of viral envelope glycoproteins to elicit broad and potent neutralizing antibodies. However, in the presence of fusion inhibitor enfuvirtide, we show that the nonneutralizing antibodies induced by the HIV type 1 (HIV-1) gp41 N-terminal heptad repeat (NHR) domain (N63) exhibit potent and broad neutralizing activity against laboratory-adapted HIV-1 strains, including the drug-resistant variants, and primary HIV-1 isolates with different subtypes, suggesting the potential of developing gp41-targeted HIV therapeutic vaccines.
authors.affiliation: Key Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College and Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Wang
authors.affiliation: Key Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College and Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
authors.forename: Wenwen
authors.initials: W
authors.lastname: Bi
authors.affiliation: Key Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College and Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
authors.forename: Xiaojie
authors.initials: X
authors.lastname: Zhu
authors.affiliation: Key Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College and Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
authors.forename: Haoyang
authors.initials: H
authors.lastname: Li
authors.affiliation: Key Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College and Shanghai Public Health Clinical Center, Fudan University, Shanghai, China Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA.
authors.forename: Qianqian
authors.initials: Q
authors.lastname: Qi
authors.affiliation: Key Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College and Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
authors.forename: Fei
authors.initials: F
authors.lastname: Yu
authors.affiliation: Key Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College and Shanghai Public Health Clinical Center, Fudan University, Shanghai, China lul@fudan.edu.cn shibojiang@fudan.edu.cn.
authors.forename: Lu
authors.initials: L
authors.lastname: Lu
authors.affiliation: Key Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College and Shanghai Public Health Clinical Center, Fudan University, Shanghai, China Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA lul@fudan.edu.cn shibojiang@fudan.edu.cn.
authors.forename: Shibo
authors.initials: S
authors.lastname: Jiang
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology*; D000077560:Enfuvirtide; D015483:HIV Antibodies / Q000276:immunology*; D015700:HIV Envelope Protein gp41 / Q000276:immunology* / Q000494:pharmacology*; D023581:HIV Fusion Inhibitors / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects* / Q000276:immunology*; D006801:Humans; D051379:Mice; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000494:pharmacology*; D011817:Rabbits
chemical_list: D057134:Antibodies, Neutralizing; D015483:HIV Antibodies; D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; C514787:gp41 protein, Human immunodeficiency virus 1; D000077560:Enfuvirtide